Evidence map›Paper›PMID 40328918›Full record

SynthesisNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2025

Multi-ancestry genome-wide association meta-analysis of buprenorphine treatment response.

Christal N Davis, Yousef Khan, Richard C Crist, Rachel Vickers-Smith, Emily E Hartwell, Joel Gelernter, Kyle Kampman, Rachel L Kember, Anne Le Moigne, Celine M Laffont and 1 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Christal N Davis *Mental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4, Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104, USA.
Yousef Khan *Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
Richard C CristMental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4, Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104, USA.
Rachel Vickers-SmithMental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4, Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104, USA.
Emily E HartwellMental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4, Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104, USA.
Joel GelernterVeterans Affairs Connecticut Healthcare System, West Haven, CT, 06516, USA.ORCID http://orcid.org/0000-0002-4067-1859
Kyle KampmanMental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4, Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104, USA.
Rachel L KemberMental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4, Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104, USA.ORCID http://orcid.org/0000-0001-8820-2659
Anne Le MoigneIndivior Inc., North Chesterfield, Chesterfield, VA, 23235, USA.
Celine M LaffontIndivior Inc., North Chesterfield, Chesterfield, VA, 23235, USA.ORCID http://orcid.org/0000-0001-8345-5980
Henry R KranzlerMental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4, Crescenz Veterans Affairs Medical Center, Philadelphia, PA, 19104, USA. kranzler@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-1018-0450

Funding

Radiochemistry CoreP30DA046345 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI KRANZLER, HENRY RICHARD, MACH, ROBERT H · 2019 to 2023
$9.4M
Characterizing the phenotypic spectrum associated with genetic liability for alcohol use disorderK01AA028292 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI KEMBER, RACHEL LORRAINE · 2021 to 2024
$505k
BLRD VA I01 BX004820CSRD VA I01 CX001734CSRD VA IK2 CX002336Indivior (Indivior PLC) noneNIAAA NIH HHS K01 AA028292NIDA NIH HHS P30 DA046345U.S. Department of Veterans Affairs (Department of Veterans Affairs) Postdoctoral fellowshipU.S. Department of Veterans Affairs (Department of Veterans Affairs) VISN 4 Mental Illness Research, Education and Clinical Center
6 · The paper itself

Abstract

Although the mu-opioid partial agonist buprenorphine is increasingly being prescribed to treat opioid use disorder, patients' responses to the drug vary and few clinical and no genetic predictors of treatment response have been identified. We conducted a genome-wide association study (GWAS) meta-analysis of buprenorphine treatment response (defined using urine drug screen results) in 4394 Veterans with opioid use disorder from the VA Million Veteran Program (751 of African-like ancestry [AFR] and 3643 of European-like ancestry [EUR]) and 296 participants from a clinical trial of extended-release buprenorphine (n

Indexed as

Analgesics, OpioidBuprenorphineGenome-Wide Association StudyOpiate Substitution TreatmentOpioid-Related DisordersAdultBlack or African AmericanFemaleHumansMaleMiddle AgedPolymorphism, Single NucleotideTreatment OutcomeVeteransWhiteAnalgesics, OpioidBuprenorphine

Identifiers

PMID40328918
PMCPMC12260092

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.